Beryl Drugs (524606)
STALWARTScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹29.11 |
| Market Cap | ₹15.46 Cr |
| P/E Ratio | 1,000 |
| ROCE | 10.15% |
| ROE | 0.15% |
| Dividend Yield | 0% |
| Profit Growth | -440% |
| Debt/Equity | — |
| Sales Growth | -28.7% |
| 52-Week Range | ₹15.92 — ₹30 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹18.52 |
Beryl Drugs trades with a P/E ratio of 1,000, ROCE of 10.15%, ROE of 0.15%, profit growth of -440%.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer